Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester, UK; NIHR Manchester Biomedical Research Centre, Manchester, UK.
Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Lancet. 2021 Apr 3;397(10281):1301-1315. doi: 10.1016/S0140-6736(20)32549-6.
Psoriasis is a common, chronic papulosquamous skin disease occurring worldwide, presenting at any age, and leading to a substantial burden for individuals and society. It is associated with several important medical conditions, including depression, psoriatic arthritis, and cardiometabolic syndrome. Its most common form, chronic plaque or psoriasis vulgaris, is a consequence of genetic susceptibility, particularly in the presence of the HLA-C*06:02 risk allele, and of environmental triggers such as streptococcal infection, stress, smoking, obesity, and alcohol consumption. There are several phenotypes and research has separated pustular from chronic plaque forms. Immunological and genetic studies have identified IL-17 and IL-23 as key drivers of psoriasis pathogenesis. Immune targeting of these cytokines and of TNFα by biological therapies has revolutionised the care of severe chronic plaque disease. Psoriasis cannot currently be cured, but management should aim to minimise physical and psychological harm by treating patients early in the disease process, identifying and preventing associated multimorbidity, instilling lifestyle modifications, and employing a personalised approach to treatment.
银屑病是一种常见的、慢性的丘疹鳞屑性皮肤病,在全球范围内发生,可发生于任何年龄,给个人和社会带来了巨大的负担。它与几种重要的医学疾病有关,包括抑郁症、银屑病关节炎和代谢综合征。其最常见的形式,慢性斑块型或寻常型银屑病,是遗传易感性的结果,特别是在 HLA-C*06:02 风险等位基因存在的情况下,以及链球菌感染、压力、吸烟、肥胖和饮酒等环境触发因素的存在。存在几种表型,研究已经将脓疱型与慢性斑块型区分开来。免疫和遗传研究已经确定了 IL-17 和 IL-23 是银屑病发病机制的关键驱动因素。生物疗法对这些细胞因子和 TNFα 的免疫靶向治疗彻底改变了严重慢性斑块疾病的治疗方法。目前银屑病无法治愈,但管理的目标应该是通过在疾病早期治疗患者、识别和预防相关的多种合并症、灌输生活方式改变和采用个性化的治疗方法,最大限度地减少身体和心理伤害。